NASDAQ:GPCR Structure Therapeutics (GPCR) Stock Price, News & Analysis $38.65 +0.34 (+0.89%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$38.25▼$39.5050-Day Range$33.76▼$56.3052-Week Range$25.57▼$75.02Volume575,115 shsAverage Volume833,133 shsMarket Capitalization$1.80 billionP/E RatioN/ADividend YieldN/APrice Target$85.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Structure Therapeutics alerts: Email Address Structure Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside120.6% Upside$85.25 Price TargetShort InterestBearish21.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.55Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.94) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.57 out of 5 starsMedical Sector717th out of 936 stocksPharmaceutical Preparations Industry334th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingStructure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageStructure Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Structure Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted21.25% of the float of Structure Therapeutics has been sold short.Short Interest Ratio / Days to CoverStructure Therapeutics has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Structure Therapeutics has recently increased by 19.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldStructure Therapeutics does not currently pay a dividend.Dividend GrowthStructure Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GPCR. Previous Next 2.0 News and Social Media Coverage News SentimentStructure Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Structure Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 14 people have searched for GPCR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Structure Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Structure Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.43% of the stock of Structure Therapeutics is held by insiders.Percentage Held by Institutions91.78% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Structure Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Structure Therapeutics are expected to grow in the coming year, from ($0.94) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Structure Therapeutics is -50.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Structure Therapeutics is -50.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStructure Therapeutics has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Structure Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Structure Therapeutics Stock (NASDAQ:GPCR)Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More GPCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GPCR Stock News HeadlinesJuly 3, 2024 | marketbeat.comAltimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer? (GPCR)Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseasesJuly 2, 2024 | marketbeat.comPfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes (GPCR)Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and WegovyJuly 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 24 at 1:37 PM | markets.businessinsider.comBuy Rating Backed by Strategic Partnership Opportunities and Strong Patent Portfolio for Structure TherapeuticsJuly 22, 2024 | fool.comMissed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.July 20, 2024 | americanbankingnews.comComparing Shuttle Pharmaceuticals (NASDAQ:SHPH) & Structure Therapeutics (NASDAQ:GPCR)July 19, 2024 | msn.comRoche obesity-pill trial results weigh on shares of Eli Lilly, Novo NordiskJuly 19, 2024 | msn.comObesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?July 26, 2024 | Colonial Metals (Ad)Collapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.July 18, 2024 | americanbankingnews.comStructure Therapeutics Inc. (NASDAQ:GPCR) Given Average Recommendation of "Buy" by AnalystsJuly 12, 2024 | investorplace.comThe 3 Most Undervalued Biotech Stocks to Buy in July 2024June 28, 2024 | investorplace.comThe 3 Smartest Biotech Stocks to Buy With $5K Right NowJune 17, 2024 | fool.comCould Structure Therapeutics Become the Next Novo Nordisk?June 14, 2024 | seekingalpha.comStructure Therapeutics: Yet Another Potential GLP-1 EntrantJune 11, 2024 | fool.comStructure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?June 9, 2024 | fool.comStructure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?June 7, 2024 | globenewswire.comStructure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary SharesJune 5, 2024 | globenewswire.comStructure Therapeutics Announces Pricing of Upsized $476 Million Public OfferingSee More Headlines Receive GPCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GPCR CUSIPN/A CIK1888886 Webwww.structuretx.com Phone628-229-9277FaxN/AEmployees93Year FoundedN/APrice Target and Rating Average Stock Price Target$85.25 High Stock Price Target$100.00 Low Stock Price Target$65.00 Potential Upside/Downside+120.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,620,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.28% Return on Assets-28.21% Debt Debt-to-Equity RatioN/A Current Ratio19.05 Quick Ratio19.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.77 per share Price / Book3.96Miscellaneous Outstanding Shares46,620,000Free Float42,223,000Market Cap$1.80 billion OptionableOptionable Beta-3.58 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Raymond C. Stevens Ph.D. (Age 60)CEO & Director Comp: $890.38kMr. Jun S. Yoon (Age 46)Co- Founder, CFO & Secretary Comp: $627.64kDr. Mark A. Bach M.D. (Age 67)Ph.D., Chief Medical Officer Comp: $672.06kDr. Yingli Ma Ph.D. (Age 50)Chief Technology Officer Comp: $497.58kDr. Xichen Lin Ph.D. (Age 50)Chief Scientific Officer Mr. Tony PengSenior Vice President of LegalMr. Bob GatmaitanSenior Vice President of PeopleDr. Hui Lei Ph.D.Senior Vice President of ChemistryDr. Fang Zhang Ph.D.Executive VP & Head of BiologyMs. Lani IbarraSenior Vice President of Clinical Development OperationsMore ExecutivesKey CompetitorsElanco Animal HealthNYSE:ELANCytokineticsNASDAQ:CYTKMadrigal PharmaceuticalsNASDAQ:MDGLViking TherapeuticsNASDAQ:VKTXOrganon & Co.NYSE:OGNView All CompetitorsInstitutional OwnershipAllspring Global Investments Holdings LLCSold 2,818 shares on 7/26/2024Ownership: 0.095%AlphaCentric Advisors LLCSold 1,500 shares on 7/26/2024Ownership: 0.056%Mather Group LLC.Bought 5,000 shares on 7/9/2024Ownership: 0.011%Teachers Retirement System of The State of KentuckyBought 2,077 shares on 5/28/2024Ownership: 0.029%Virtu Financial LLCBought 7,186 shares on 5/20/2024Ownership: 0.015%View All Institutional Transactions GPCR Stock Analysis - Frequently Asked Questions How have GPCR shares performed this year? Structure Therapeutics' stock was trading at $40.76 on January 1st, 2024. Since then, GPCR shares have decreased by 5.2% and is now trading at $38.65. View the best growth stocks for 2024 here. How were Structure Therapeutics' earnings last quarter? Structure Therapeutics Inc. (NASDAQ:GPCR) released its quarterly earnings results on Thursday, May, 9th. The company reported ($0.19) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.02. When did Structure Therapeutics IPO? Structure Therapeutics (GPCR) raised $150 million in an initial public offering on Friday, February 3rd 2023. The company issued 10,740,000 shares at a price of $13.00-$15.00 per share. Who are Structure Therapeutics' major shareholders? Top institutional investors of Structure Therapeutics include Allspring Global Investments Holdings LLC (0.10%), AlphaCentric Advisors LLC (0.06%) and Mather Group LLC. (0.01%). How do I buy shares of Structure Therapeutics? Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GPCR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.